SCHEMBL6295563

SCHEMBL6295563

O=C(O)C=Cc1cc2cc(Cl)c(Cl)cc2[nH]1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ATP6AP1 Q15904 1/20 0.53
ATP6V1B1 P15313 3/20 0.41
KDM4E B2RXH2 1/20 0.38
BLM P54132 1/20 0.38
NPSR1 Q6W5P4 1/20 0.38
CYP3A4 P08684 1/20 0.38
TSHR P16473 1/20 0.38
PTGER1 P34995 1/20 0.37
PTGER3 P43115 1/20 0.37
PTGER2 P43116 1/20 0.37
GRIN2D O15399 1/20 0.36
GRIN3B O60391 1/20 0.36
LMNA P02545 1/20 0.36
GRIK1 P39086 1/20 0.36
GRIA1 P42261 1/20 0.36
GRIA2 P42262 1/20 0.36
GRIA3 P42263 1/20 0.36
GRIA4 P48058 1/20 0.36
GRIN1 Q05586 1/20 0.36
GRIN2A Q12879 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6295560 1.00 ATP6AP1 (0.53) ATP6AP1ATP6V1B1KDM4EBLMNPSR1
SCHEMBL15466242 0.81 ALOX15 (0.50)
SCHEMBL17908002 0.81 F7 (0.55) KDM4ELMNA
SCHEMBL17908005 0.81 F7 (0.55) KDM4ELMNA
SCHEMBL15466243 0.81 ALOX15 (0.50)
SCHEMBL8308919 0.78 ATP6AP1 (0.52) ATP6AP1ATP6V1B1KDM4ECYP3A4
SCHEMBL8308921 0.78 ATP6AP1 (0.52) ATP6AP1ATP6V1B1KDM4ECYP3A4
SCHEMBL8444640 0.76 ATP6AP1 (0.63) ATP6AP1ATP6V1B1GRIN2DGRIN3BLMNA
SCHEMBL8444639 0.76 ATP6AP1 (0.63) ATP6AP1ATP6V1B1GRIN2DGRIN3BLMNA
SCHEMBL6292617 0.76 ATP6AP1 (0.56) ATP6AP1ATP6V1B1KDM4EBLMNPSR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6903117-B2 Indole derivatives for the treatment of osteoporosis NIKEM RESEARCH S.R.L. (IT) 2005-06-07 US disclosed
EP-0914321-B1 INDOLE DERIVATIVES FOR THE TREATMENT OF OSTEOPOROSIS NIKEM RESEARCH SRL (IT) 2004-09-22 EP disclosed
US-20040010012-A1 Selective inhibitor of the biological activity of human osteoclast cells SMITHKLINE BEECHAM SPA 2004-01-15 US disclosed
US-20020173659-A1 Indole derivatives for the treatment of osteoporosis SMITH KLINE BEECHAM SPA 2002-11-21 US disclosed
EP-0914321-A1 INDOLE DERIVATIVES FOR THE TREATMENT OF OSTEOPOROSIS Smithkline Beecham S.p.A. (IT) 1999-05-12 EP disclosed
WO-1998001443-A1 INDOLE DERIVATIVES FOR THE TREATMENT OF OSTEOPOROSIS SMITHKLINE BEECHAM S.P.A. (IT) 1998-01-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040010012-A1 Selective inhibitor of the biological activity of human osteoclast cells HRH4, HRH3, CNKSR1 ATP6AP1 2965/4885ATP6V1B1 2556/4885KDM4E 43/4885
US-20020173659-A1 Indole derivatives for the treatment of osteoporosis SOST, GHRHR, EBP ATP6AP1 4110/4885ATP6V1B1 2108/4885KDM4E 662/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.